SCHEMBL26145337

SCHEMBL26145337

COc1ccc(-c2coc3cc(OC(C)=O)cc(O)c3c2=O)cc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.82
NPC1 O15118 8/20 0.82
SMN1; SMN2 Q16637 7/20 0.82
MEN1 O00255 5/20 0.82
KMT2A Q03164 5/20 0.82
CYP2C9 P11712 4/20 0.82
CYP2C19 P33261 4/20 0.82
NFKB1 P19838 3/20 0.82
NFKB2 Q00653 3/20 0.82
RELA Q04206 3/20 0.82
CYP2D6 P10635 3/20 0.82
CYP1A2 P05177 2/20 0.82
CYP3A4 P08684 6/20 0.79
KDM4E B2RXH2 5/20 0.79
TP53 P04637 5/20 0.79
HSD17B10 Q99714 4/20 0.79
ALDH1A1 P00352 6/20 0.76
MAPT P10636 6/20 0.76
HPGD P15428 4/20 0.76
MAOA P21397 3/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
7-Acetoxy-4',5-Dihydroxygenistein SCHEMBL10001910 0.92 ALDH2 (0.75) RAB9ANPC1SMN1; SMN2MEN1KMT2A
4',7-Dimethoxy-5-Hydroxygenistein SCHEMBL572108 0.90 RAB9A (1.00) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL26145340 0.90 RAB9A (0.77) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL29936595 0.88 KDM4E (1.00) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL26145311 0.88 KDM4E (1.00) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL26145341 0.88 RAB9A (0.77) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL6142590 0.88 RAB9A (0.77) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL26145332 0.88 RAB9A (0.77) RAB9ANPC1SMN1; SMN2MEN1KMT2A
Biochanin SCHEMBL61258 0.87 RAB9A (1.00) RAB9ANPC1SMN1; SMN2MEN1KMT2A
Biochanin SCHEMBL29410271 0.87 RAB9A (1.00) RAB9ANPC1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149344-A1 BIOCHANIN A DERIVATIVES FOR TREATMENT OF BEST1-RELATED RETINOPATHIES UNIVERSITÄT REGENSBURG (AT) 2023-05-18 US disclosed
US-20230149344-A1 BIOCHANIN A DERIVATIVES FOR TREATMENT OF BEST1-RELATED RETINOPATHIES UNIVERSITÄT REGENSBURG (AT) 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149344-A1 BIOCHANIN A DERIVATIVES FOR TREATMENT OF BEST1-RELATED RETINOPATHIES SORBS1, SLC5A6, SLC20A1 RAB9A 1919/4885NPC1 1509/4885SMN1; SMN2 252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.